TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Pulse Biosciences Inc (NASDAQ:PLSE) Investor Investigation Over Potential Securities Laws Violations Announced

  • If you purchased shares of Pulse Biosciences Inc (NASDAQ:PLSE), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Security

Summary

Update (08/30/2018) - On July 31, 2018, Pulse Biosciences Inc disclosed that it had received subpoenas from the U.S. Securities and Exchange Commission requesting documents and information related to an investigation into trading in the company's stock in advance of its September 2017 financing announcement. Pulse Biosciences Inc further revealed that on July 30, 2018, the company received a letter from Nasdaq stating that Pulse Biosciences Inc is not in compliance with Nasdaq's audit committee requirements and has until July 27, 2019 to regain compliance.

An investigation on behalf of investors of Pulse Biosciences Inc (NASDAQ:PLSE) shares over potential securities laws violations by Pulse Biosciences Inc and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Pulse Biosciences Inc (NASDAQ:PLSE) concerning whether a series of statements by Pulse Biosciences Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Hayward, CA based Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). Shares of Pulse Biosciences Inc (NASDAQ:PLSE) grew from $6.17 per share in early 2017 to as high as $37.60 per share in June 2017.

On September 11, 2017, Pulse Biosciences Inc disclosed that it has withdrawn its initial application to the United States Food and Drug Administration (FDA) for 510(k) clearance of its PulseTxTM System. Pulse Biosciences Inc further disclosed that the voluntary withdrawal on September 8, 2017, was the result of the FDAs appropriate request for additional data that could not be provided within the Agencys 90-day review period that would have otherwise ended on September 10, 2017.

Shares of Pulse Biosciences Inc (NASDAQ:PLSE) declined to as low as $9.94 per share on September 13, 2017.

Start Monitoring Your Investments